Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 2,036,865 shares changed hands during trading, an increase of 202% from the previous session's volume of 675,175 shares.The stock last traded at $107.66 and had previously closed at $109.32.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research reports. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating for the company in a research report on Friday, July 12th. Needham & Company LLC lowered their price target on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Piper Sandler reduced their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 1st. Finally, Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $173.07.

Jazz Pharmaceuticals Trading Down 0.6 %

The company has a 50-day moving average price of $109.69 and a 200 day moving average price of $112.53. The stock has a market capitalization of $6.85 billion, a P/E ratio of 22.40, a price-to-earnings-growth ratio of 1.45 and a beta of 0.58. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of JAZZ. Point72 Asset Management L.P. grew its holdings in Jazz Pharmaceuticals by 20,323.9% in the second quarter. Point72 Asset Management L.P. now owns 182,015 shares of the specialty pharmaceutical company's stock worth $19,427,000 after purchasing an additional 182,915 shares during the last quarter. Systematic Financial Management LP grew its stake in Jazz Pharmaceuticals by 5.7% during the 2nd quarter. Systematic Financial Management LP now owns 254,330 shares of the specialty pharmaceutical company's stock worth $27,145,000 after buying an additional 13,651 shares during the last quarter. Creative Planning increased its position in Jazz Pharmaceuticals by 21.7% during the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company's stock valued at $408,000 after buying an additional 680 shares in the last quarter. Algert Global LLC purchased a new stake in Jazz Pharmaceuticals in the second quarter valued at about $637,000. Finally, MidWestOne Financial Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 62.9% during the second quarter. MidWestOne Financial Group Inc. now owns 20,929 shares of the specialty pharmaceutical company's stock worth $2,234,000 after acquiring an additional 8,083 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.